Terremoto Biosciences, Inc.

The slowdown in financings across the biopharmaceutical spectrum hit private and public companies alike in 2023 and the latest venture capital fundraising data from Evaluate indicate that last year di

October ended and November began with the announcement of three new venture capital and equity funds with more than $1.3bn for health care, life science and biopharmaceutical investments. Revelation P

Even with less venture capital raised during the first quarter of 2022 than in Q1 of 2021, VC financing has become the most common type of financing for biopharmaceutical firms raising cash in 2022, a